	US 12,439,944 B2
	3-hydroxybutyrate compounds for use in reducing liver fat
Kieran Clarke, Oxford (GB)
Assigned to TDeltaS Limited, Thame (GB)
Appl. No. 16/626,293
Filed by TDeltaS Limited, Thame (GB)
PCT Filed Jun. 22, 2018, PCT No. PCT/GB2018/051752 § 371(c)(1), (2) Date Dec. 23, 2019, PCT Pub. No. WO2019/002828, PCT Pub. Date Jan. 3, 2019.
Claims priority of application No. 1710229 (GB), filed on Jun. 27, 2017.
Prior Publication US 2020/0113220 A1, Apr. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A23L 33/10 (2016.01); A23L 33/00 (2016.01)

CPC A23L 33/10 (2016.08) [A23L 33/30 (2016.08); A23V 2002/00 (2013.01)]

20 Claims

1. A method of reducing liver fat in a subject having a fatty liver, but not non-alcoholic steatohepatitis or alcoholic steatohepatitis, the method comprising orally administering to the subject (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate or a pharmaceutically acceptable salt or solvate thereof in an amount of the (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate effective to reduce liver fat in the subject.